Hernandezine (Synonyms: Hernandesine)

Name: Hernandezine
Brand: MedChemExpress
SKU: HY-N6042
Rating: 4.5 (1 reviews)

Cat. No.: HY-N6042 Purity: ≥99.0%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Hernandezine (Hernandesine) is isolated from Thalictrum glandulosissimum.

For research use only. We do not sell to patients.

Hernandezine Chemical Structure

CAS No. : 6681-13-6

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Hernandezine

•Phytomedicine. 2024 May 28:131:155775. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Hernandezine (Hernandesine) is isolated from Thalictrum glandulosissimum^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	7.2 μM Compound: HER	Cytotoxicity against human A-375 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35544345]
A549	IC₅₀	7.59 μM Compound: HER	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 35544345]
B16	IC₅₀	5.9 μM Compound: HER	Cytotoxicity against mouse B16 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35544345]
HEK293	IC₅₀	0.07 μM Compound: Hernandezine	Potentiation of etoposide-induced cytotoxicity against HEK293 cells assessed as etoposide IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 0.11 +/- 0.03 nM) Potentiation of etoposide-induced cytotoxicity against HEK293 cells assessed as etoposide IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 0.11 +/- 0.03 nM)	[PMID: 27504669]
HEK293	IC₅₀	1.21 nM Compound: Hernandezine	Potentiation of mitoxantrone-induced cytotoxicity against HEK293 cells assessed as mitoxantrone IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 1 +/- 0.19 nM) Potentiation of mitoxantrone-induced cytotoxicity against HEK293 cells assessed as mitoxantrone IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 1 +/- 0.19 nM)	[PMID: 27504669]
HEK293	IC₅₀	109 nM Compound: Hernandezine	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	[PMID: 27504669]
HEK293	IC₅₀	25.27 nM Compound: Hernandezine	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	[PMID: 27504669]
HEK293	IC₅₀	3.85 nM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM) Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	[PMID: 27504669]
HEK293	IC₅₀	300 nM Compound: Hernandezine	Inhibition of human ABCB1-mediated efflux transfected in HEK293 cells assessed as accumulation of fluorescent dye by calcein-AM dye based FACS analysis Inhibition of human ABCB1-mediated efflux transfected in HEK293 cells assessed as accumulation of fluorescent dye by calcein-AM dye based FACS analysis	[PMID: 27504669]
HEK293	IC₅₀	38.32 μM Compound: Hernandezine	Inhibition of human ABCC1 transfected in HEK293 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring etoposide IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 38.54 +/- 5.62 nM) Inhibition of human ABCC1 transfected in HEK293 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring etoposide IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 38.54 +/- 5.62 nM)	[PMID: 27504669]
HEK293	IC₅₀	43.93 nM Compound: Hernandezine	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	[PMID: 27504669]
HEK293	IC₅₀	5.63 nM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM) Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	[PMID: 27504669]
HEK293	IC₅₀	6.81 nM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM) Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	[PMID: 27504669]
HEK293	IC₅₀	6.99 nM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM) Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	[PMID: 27504669]
HEK293	IC₅₀	75.77 nM Compound: Hernandezine	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	[PMID: 27504669]
HEK293	IC₅₀	85.08 nM Compound: Hernandezine	Inhibition of human ABCG2 R482 mutant transfected in HEK293 cells assessed as potentiation of mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 107.40 +/- 13.93 nM) Inhibition of human ABCG2 R482 mutant transfected in HEK293 cells assessed as potentiation of mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 107.40 +/- 13.93 nM)	[PMID: 27504669]
Hep 3B2	IC₅₀	6.71 μM Compound: HER	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 35544345]
HepG2	IC₅₀	7.42 μM Compound: HER	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 35544345]
KB 3-1	IC₅₀	0.11 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM) Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.13 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM) Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.14 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM) Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.15 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM) Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.59 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM) Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.62 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM) Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.63 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM) Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.63 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM) Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	9.15 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 100 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM) Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 100 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	9.29 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 500 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM) Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 500 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	9.33 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 200 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM) Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 200 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	9.77 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 8.81 +/- 3.80 nM) Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 8.81 +/- 3.80 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	0.23 μM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	0.55 μM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	1.31 μM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	1009.5 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	115.02 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	2.81 μM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	223.72 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	2660.5 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	3220.21 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	571.36 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	79.31 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	969.58 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	[PMID: 27504669]
NCI-H1299	IC₅₀	6.74 μM Compound: HER	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability by MTT assay	[PMID: 35544345]
OVCAR-8	IC₅₀	0.1 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM) Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	[PMID: 27504669]
OVCAR-8	IC₅₀	0.11 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM) Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	[PMID: 27504669]
OVCAR-8	IC₅₀	0.11 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM) Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	[PMID: 27504669]
OVCAR-8	IC₅₀	0.12 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM) Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	[PMID: 27504669]
OVCAR-8	IC₅₀	20.45 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM) Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	22.11 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM) Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	22.75 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM) Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	24.53 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM) Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	4.94 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM) Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	6.02 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM) Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	6.14 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM) Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	6.38 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM) Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	[PMID: 27504669]

Molecular Weight

652.78

Formula

C₃₉H₄₄N₂O₇

CAS No.

6681-13-6

Appearance

Solid

Color

White to off-white

SMILES

COC1=C(O2)C3=C(CCN(C)[C@@]3([H])CC4=CC=C(OC)C(OC5=CC=C(C=C5)C[C@@]6([H])C7=C(CCN6C)C=C(OC)C2=C7)=C4)C(OC)=C1OC

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 6.25 mg/mL (9.57 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5319 mL	7.6595 mL	15.3191 mL
5 mM	0.3064 mL	1.5319 mL	3.0638 mL
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.62 mg/mL (0.95 mM); Clear solution

This protocol yields a clear solution of ≥ 0.62 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 0.62 mg/mL (0.95 mM); Clear solution

This protocol yields a clear solution of ≥ 0.62 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥99.0%

Select Batch:

Data Sheet (277 KB) SDS (251 KB)

COA (257 KB) HNMR (130 KB) CNMR (136 KB) RP-HPLC (548 KB)

Handling Instructions (2659 KB)

References

[1]. Ropivia J, et al. Isoquinolines from the roots of Thalictrum flavum L. and their evaluation as antiparasitic compounds. Molecules. 2010 Sep 16;15(9):6476-84. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.5319 mL	7.6595 mL	15.3191 mL	38.2977 mL
DMSO	5 mM	0.3064 mL	1.5319 mL	3.0638 mL	7.6595 mL

Hernandezine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Hernandezine6681-13-6HernandesineOthersInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Hernandezine (Synonyms: Hernandesine)

Customer Review

Hernandezine Related Antibodies

1 Publications Citing Use of MCE Hernandezine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Hernandezine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report